Raygan Fariba, Rezavandi Zohreh, Bahmani Fereshteh, Ostadmohammadi Vahidreza, Mansournia Mohammad Ali, Tajabadi-Ebrahimi Maryam, Borzabadi Shokoofeh, Asemi Zatollah
1Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
2Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Diabetol Metab Syndr. 2018 Jun 19;10:51. doi: 10.1186/s13098-018-0353-2. eCollection 2018.
This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles in diabetic patients with coronary heart disease (CHD).
This randomized, double-blind, placebo-controlled trial was performed among 60 diabetic patients with CHD, aged 40-85 years at a cardiology clinic in Kashan, Iran, from October 2017 through January 2018. Patients were randomly divided into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at the beginning of the study and after the 12-week intervention to determine related markers.
After 12-week intervention, probiotic supplementation significantly decreased fasting plasma glucose (β - 20.02 mg/dL; 95% CI - 33.86, - 6.17; = 0.005), insulin (β - 2.09 µIU/mL; 95% CI - 3.77, - 0.41; = 0.01), insulin resistance (β - 0.50; 95% CI - 0.96, - 0.03; = 0.03) and total-/HDL-cholesterol ratio (β - 0.27; 95% CI - 0.52, - 0.03; = 0.02), and significantly increased insulin sensitivity (β 0.008; 95% CI 0.001, 0.01; = 0.02) and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 5.00; = 0.04) compared with the placebo. Moreover, probiotic supplementation led to a significant reduction in serum high sensitivity C-reactive protein (β - 0.88 mg/L; 95% CI - 1.39, - 0.38; = 0.001), and a significant elevation in total antioxidant capacity (β 108.44 mmol/L; 95% CI 47.61, 169.27; = 0.001) and total glutathione levels (β 45.15 µmol/L; 95% CI 5.82, 84.47; = 0.02) compared with the placebo. Probiotic supplementation did not affect other metabolic profiles.
Overall, we found that probiotic supplementation for 12 weeks had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, biomarkers of inflammation and oxidative stress in diabetic patients with CHD. Clinical trial registration number http://www.irct.ir: IRCT2017082733941N5.
本研究旨在评估补充益生菌对冠心病（CHD）糖尿病患者代谢谱的影响。
本随机、双盲、安慰剂对照试验于2017年10月至2018年1月在伊朗卡尚的一家心脏病诊所对60例年龄在40 - 85岁的冠心病糖尿病患者进行。患者被随机分为两组，分别服用益生菌补充剂（n = 30）或安慰剂（n = 30），为期12周。在研究开始时和12周干预后采集空腹血样以测定相关指标。
经过12周干预，与安慰剂相比，补充益生菌显著降低了空腹血糖（β - 20.02mg/dL；95%CI - 33.86，- 6.17；P = 0.005）、胰岛素（β - 2.09µIU/mL；95%CI - 3.77，- 0.41；P = 0.01）、胰岛素抵抗（β - 0.50；95%CI - 0.96, - 0.03；P = 0.03）和总胆固醇/高密度脂蛋白胆固醇比值（β - 0.27；95%CI - 0.52，- 0.03；P = 0.02），并显著提高了胰岛素敏感性（β 0.008；95%CI 0.001，0.01；P = 0.02）和高密度脂蛋白胆固醇水平（β 2.52mg/dL；95%CI 0.04，5.00；P = 0.04）。此外，与安慰剂相比，补充益生菌导致血清高敏C反应蛋白显著降低（β - 0.88mg/L；95%CI - 1.39，- 0.38；P = 0.001），总抗氧化能力显著升高（β 108.44mmol/L；95%CI 47.61，169.27；P = 0.001）和总谷胱甘肽水平显著升高（β 45.15µmol/L；95%CI 5.82，84.47；P = 0.02）。补充益生菌未影响其他代谢谱。
总体而言，我们发现补充益生菌12周对冠心病糖尿病患者的血糖控制、高密度脂蛋白胆固醇、总胆固醇/高密度脂蛋白胆固醇比值、炎症和氧化应激生物标志物具有有益影响。临床试验注册号http://www.irct.ir：IRCT2017082733941N5。
